## Accepted Manuscript

Novel furocoumarins as potential HIV-1 integrase inhibitors

Temitope O. Olomola, Salerwe Mosebi, Rosalyn Klein, Telisha Traut-Johnstone, Judy Coates, Raymond Hewer, Perry T. Kaye

PII:	S0045-2068(14)00061-3
DOI:	http://dx.doi.org/10.1016/j.bioorg.2014.07.008
Reference:	YBIOO 1744
To appear in:	Bioorganic Chemistry
	<b>AD 16 A A A A</b>





Please cite this article as: T.O. Olomola, S. Mosebi, R. Klein, T. Traut-Johnstone, J. Coates, R. Hewer, P.T. Kaye, Novel furocoumarins as potential HIV-1 integrase inhibitors, *Bioorganic Chemistry* (2014), doi: http://dx.doi.org/10.1016/j.bioorg.2014.07.008

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## **Novel Furocoumarins as Potential HIV-1 Integrase Inhibitors**

Temitope O. Olomola,<sup>a</sup> Salerwe Mosebi,<sup>b</sup> Rosalyn Klein,<sup>a</sup> Telisha Traut-Johnstone,<sup>b</sup> Judy Coates,<sup>b</sup> Raymond Hewer<sup>b</sup> and Perry T. Kaye<sup>a</sup>\*

<sup>a</sup>Department of Chemistry and Centre for Chemico- and Biomedicinal Research, Rhodes University, Grahamstown, 6140, South Africa. <sup>b</sup>Biomed, Advanced Materials Division, Mintek, Randburg, 2125, South Africa.

**ABSTRACT.** A series of seven novel, rationally designed *N*-substituted  $3-\{3,5-dimethylfuro[3,2-g]$ coumarin-6-yl}propanamides have been prepared as potential HIV-1 integrase (IN) inhibitors *via* a five-step pathway commencing with resorcinol and diethyl 2-acetylglutarate, and the HIV-1 IN inhibition potential of these compounds has been examined relative to raltegravir, a known HIV-1 IN inhibitor.

Key Words: Furocoumarins, HIV-1 integrase, strand-transfer inhibitors, rational design

#### 1. Introduction.

Earlier research on the development of effective anti-HIV agents has focussed on inhibitors of the critical HIV-1 enzymes, reverse transcriptase (RT) and protease (PR).<sup>1,2</sup> The emerging challenges of drug resistance have been addressed using combinations of RT and PR inhibitors in what is known as 'Highly Active Anti-Retroviral Therapy (HAART)' –an approach which has enjoyed considerable success.<sup>3</sup> Nevertheless, there is an urgent need to develop new and more effective therapeutics and the drug targets have been extended to include HIV-1 integrase (IN) inhibitors,<sup>4</sup> which either block the strand transfer of viral DNA into the host genome or disrupt the 3'-processing of the viral DNA LTR units.<sup>5</sup> Since the approval of raltegravir 1<sup>6</sup> for clinical use by the FDA in 2007, other potential scaffolds have been explored, *inter alia* the  $\beta$ -diketo acid (DKA) moiety,<sup>7</sup> which is present in compound 2<sup>8</sup> and which is capable of coordinating metal ions in the enzyme active site.



<sup>\*</sup>To whom correspondence should be addressed. Prof. P.T. Kaye, E-mail: P.Kaye@ru.ac.za;

Tel. +27 46 6038268.Department of Chemistry, Rhodes University, Grahamstown, 6140, South Africa.

#### 2. Results and Discussion.

Computer modelling studies suggested that the endocyclic oxygens in furocoumarin derivatives, such as compound **3a** (Figure 1), could also coordinate metal ions in the HIV-1 IN enzyme active site and inhibit the integration of viral DNA. The coumarin moiety is found in various medicinally active natural products, including umbilliferone (7-hydroxycoumarin)<sup>9</sup> and warfarin.<sup>10.</sup> In our own research on applications of Baylis-Hillman chemistry, we have reported several approaches to coumarins and their elaboration to novel analogues<sup>11</sup> of the clinically established HIV-1 PR inhibitor, ritonavir, and, more recently, the synthesis and evaluation of coumarin-AZT conjugates as potential dual-action HIV-1 PR/RT inhibitors.<sup>12,13</sup> In our approach to the synthesis of the furocoumarins **3a-g** as potential HIV-1 IN inhibitors, however, we decided to follow the five-step pathway outlined in Scheme 1.



Figure 1. Computer-modelled 2-D interactions of compound **3a** with the HIV-1 IN active site obtained using Tripos Sybyl molecular modelling software.

Resorcinol **4** was reacted overnight with diethyl 2-acetylglutarate **5** at 0 °C in an ethanolic solution of HCl, generated *in situ* by the cautious addition of acetyl chloride to dry ethanol (CAUTION! exothermic reaction), and the known coumarin derivative  $6^{14}$  was isolated in 64% yield (Scheme 1). Following a literature procedure,<sup>15</sup> alkylation of the phenolic hydroxyl group in compound **6** was achieved by treatment with highly lachrymatory chloroacetone in the presence of freshly calcined K<sub>2</sub>CO<sub>3</sub>; the intermediate **7** was obtained, after recrystallisation, in 73% yield. The critical furanocoumarin scaffold **8** was obtained in good yield (79% after recrystallisation) by heating the ether **7** under basic conditions.<sup>15</sup> This mechanistically interesting cyclisation is considered<sup>16</sup> to proceed *via* initial opening of the coumarin ring to afford a phenoxide ion which, in turn, activates the *para*-position to intramolecular cyclisation of the ester group; subsequent protonation and acid-catalysed dehydration then regenerates the coumarin moiety

With the common scaffold,  $3-\{3,5-\text{dimethylfuro}[3,2-g]\text{coumarin-6-yl}\}$  propanoic acid **8**, in hand, access to the targeted furanocoumarin carboxamides **3a-g** was achieved in two steps, *viz.*, activation of the carboxylic acid group by treatment with *N*-hydroxysuccinimide and *N*,*N*'-diisopropylcarbodiimide (DIC) to generate the succinimido intermediates **9** (Scheme 1), followed by *in situ* reaction with each of the amines **10a-g**. The resulting, novel carboxamides **3a-g** were obtained in moderate to good yield (63 - 83% after recrystallisation;



NHR

Table 1) and fully characterised. Chromatographed samples were tested for their inhibition of the HIV-1 IN strand-transfer process using the method adapted from Hazuda *et al.*<sup>17</sup>

Scheme 1. Synthetic route to furocoumarin analogues 3a-g.

 Table 1. Yields and % HIV-1 IN strand-transfer enzyme inhibition activities for compounds 3a-g at 10 μM.
 0

		0~0~0		
	Compound	R	% Yield	% Inhibition <sup>a</sup>
	3a	(pyridine-2-yl)methyl	78	16.61 (3.11)
	3b	(furan-2-yl)methyl	80	5.21 (7.94)
Y	3c	5-(diethylamino)pent-2-yl	76	4.98 (5.96)
V	3d	(pyridine-3-yl)methyl	81	10.31 (6.62)
	<b>3</b> e	benzyl	82	11.12 (7.48)
	3f	<i>tert</i> -butyl	63	8.48 (7.44)
	<b>3</b> g	propyl	83	15.92 (7.66)
	Raltegravir	-	-	92.77 (0.61)

<sup>a</sup> Standard deviation in parentheses.

Percentage enzyme inhibition values for compounds **3a-g** and raltegravir (a known HIV-1 IN inhibitor) are reported in Table 1. While some of the synthetic ligands exhibited negligible inhibition activities at a concentration of 10  $\mu$ M, a number of compounds exhibited stastically significant inhibition (p > 0.05) at this concentration [*viz.*, **3a** (16.61%); **3d** (10.31); **3e** (11.12%); and **3g** (15.92%)] and may warrant further investigation in the development of possible lead compounds. While compounds **3a** and **3d** contain pyridyl moieties with hydrogen-bonding potential, compounds **3e** and **3g** contain non-polar moieties (benzyl and propyl, respectively). *In silico* docking studies of these specific compounds is expected to guide future developments.

#### 3. Conclusions.

The structure of a potential HIV-1 IN inhibitor has been identified from an examination of its virtual interactions with a model of the HIV-1 IN active site based on available sub-domain X-ray crystal structures and NMR structures. This compound and a series of six analogues have been successfully synthesised and HIV-1 IN inhibition studies reveal that some of the ligands exhibit statistically significant inhibition at 10  $\mu$ M concentrations. Ongoing research in this area at Rhodes is being focussed on the development of cinnamate ester-AZT and DKA analogue-AZT conjugates as potential dual-action HIV-1 integrase/reverse transcriptase inhibitors.

#### 4. Experimental.

#### 4.1. General.

NMR spectra were recorded on a Bruker AMX 400 spectrometer at 303 K in CDCl<sub>3</sub> or DMSO- $d_6$  and calibrated using solvent signals [ $\delta_{\rm H}$ : 7.26 ppm for residual CHCl<sub>3</sub> and 2.50 ppm for residual DMSO;  $\delta_{\rm C}$ : 77.0 ppm (CDCl<sub>3</sub>) and 39.5 (DMSO- $d_6$ )]. Melting points were measured using a hot stage apparatus and are uncorrected. IR spectra were recorded on a Perkin Elmer Spectrum 100 FT-IR spectrometer with a diamond window, and compounds were analysed neat. High-resolution mass spectra (HRMS) were recorded on a Waters API Q-TOF Ultima spectrometer (University of Stellenbosch, Stellenbosch, South Africa). All computational protein manipulations were performed on a dual-core desktop PC with a Red Hat Enterprise Linux Version 5.0 operating system. All protein visualisations, manipulations and docking runs were performed using the commercial software package Sybyl<sup>TM</sup> version 8.0, licensed from Tripos<sup>TM</sup> (Tripos Inc., St. Louis, MO, USA, 2008).

#### 4.2. Computer modelling.

A three-dimensional model of the HIV-1 IN active site was prepared based on subdomain X-ray crystal structures and NMR structures available in the Protein Data Bank (PDB1QS4, PDB1B9F, PDB1EX4, PDB1K6Y, PDB2B4J, PDB1MM8 and PDB1TQR). A virtual, drug-like compound database of 731 compounds was prepared through filtering of the ZINC commercial database according to Lipinski's Rule of 5. Ten different orientations of each compound were docked into the prepared HIV-1 IN active site using the SurflexDock<sup>TM</sup> application. Compound **3a** was identified as a potential inhibitor based on the virtual interactions with the enzyme active site predicted by the docking studies.

### 4.3. Chemistry.

### 4.3.1. Synthesis of intermediates 6-8.

The intermediates were obtained using reported methods: ethyl 3-(7-hydroxy-4-methylcoumarin-3-yl)propanoate **6** as a pale yellow solid (44.2 g, 64%), m.p. 126-127 °C (lit.<sup>14</sup> 124 °C); ethyl 3-[7-(2-oxopropoxy)-4-methylcoumarin-3-yl]propanoate **7** as white crystals (28.1 g, 73%), m.p. 122-123 °C (lit.<sup>15</sup> 115-116 °C); and 3-{3,5-dimethylfuro[3,2-g]coumarin-6-yl}propanoic acid **8** as a yellow solid (16.9 g, 79%), m.p. 220-221 °C (lit.<sup>15</sup> 215-216 °C). The general procedure for the synthesis of the novel furocoumarin carboxamides **3a-g** is illustrated by the following example; analytical data for the other compounds are detailed below.

## 4.3.2. Synthesis and analytical data for the furocoumarin ligands **3a-g**.

4.3.2.1. General procedure: Synthesis of 3-{3,5-Dimethylfuro[3,2-g]coumarin-6-yl}-N-[(pyridin-2-yl)methyl]-propanamide **3a**.

3-{3,5-Dimethylfuro[3,2-g]coumarin-6-yl}propanoic acid 8 (1.0 g, 3.5 mmol) was dissolved in dry dioxane (50 mL) in a 2-necked round-bottomed flask and Nhydroxysuccinimide (0.44 g, 3.8 mmol) was added. The solution was stirred under  $N_2$  for 20 min.; N,N'-diisopropylcarbodiimide (0.6 mL, 4 mmol) was then added through a septum and the solution stirred vigorously for 2 h. 2-Picolylamine 10a (0.4 mL, 4 mmol) was then introduced through the septum and the mixture stirred for 4 h at r.t. under N<sub>2</sub>. Ice-cooled water was then added to the mixture and the resulting precipitate was filtered off. Recrystallisation from 2-propanol gave 3-{3,5-dimethylfuro[3,2-g]coumarin-6-yl}-N-[(pyridin-2-yl)methyl]propanamide **3a** as a yellow solid (1.03 g, 78%), m.p. 212-213 °C [HRMS: m/z calculated for C<sub>22</sub>H<sub>21</sub>N<sub>2</sub>O<sub>4</sub> (MH<sup>+</sup>) 377.1501. Found 377.1498];  $\delta_{\rm H}$  (400 MHz; DMSO-d<sub>6</sub>) 2.26 (3H, s, 3-CH<sub>3</sub>), 2.41 (2H, t, J = 7.5 Hz, CH<sub>2</sub>Ar), 2.45 (3H, s, 5-CH<sub>3</sub>), 2.85 (2H, t, J = 7.5 Hz, CH<sub>2</sub>CO), 4.32 (2H, d, J = 5.7 Hz, NCH<sub>2</sub>), 7.18 (2H, m, ArH), 7.57 (2H, m, ArH), 7.83 (1H, s, ArH), 7.90 (1H, s, ArH), 8.42 (1H, d, J = 4.3, ArH) and 8.51 (1H, t, J = 5.7 Hz, NH); δ<sub>C</sub> (100 MHz; DMSO-d<sub>6</sub>) 7.6 and 15.2 (CH<sub>3</sub>), 23.7, 33.9 and 44.2 (CH<sub>2</sub>), 98.8, 115.6, 116.0, 116.3, 120.9, 122.0, 122.4, 125.9, 136.5, 143.6, 147.9, 148.8, 149.7, 155.2 and 158.6 (Ar-C), 160.7 and 171.5 (C=O).

### 4.3.2.2. Analytical data for the furocoumarin ligands **3b-g**.

4.3.2.2.1. 3-{3,5-Dimethylfuro[3,2-g]coumarin-6-yl}-N-[(furan-2-yl)methyl]propanamide **3b**, a yellow solid (1.02 g, 80%), m.p. 215-217 °C [HRMS: *m/z* calculated for C<sub>21</sub>H<sub>20</sub>NO<sub>5</sub> (MH<sup>+</sup>) 366.1342. Found 366.1331];  $\delta_{\rm H}$  (400 MHz; CDCl<sub>3</sub>) 2.28 (3H, s, 3-CH<sub>3</sub>), 2.53 (5H, overlapping s and t, 5-CH<sub>3</sub> and CH<sub>2</sub>Ar), 3.02 (2H, t, *J* = 7.4 Hz, CH<sub>2</sub>CO), 4.39 (2H, d, *J* = 5.5 Hz, NCH<sub>2</sub>), 6.14 (1H, d, *J* = 2.1 Hz, ArH), 6.20 (1H, m, ArH), 6.24 (1H, br s, NH), 7.17 (1H, s, ArH), 7.29 (1H, s, ArH), 7.43 (1H, s, ArH) and 7.66 (1H, s, ArH);  $\delta_{\rm C}$  (100 MHz; CDCl<sub>3</sub>) 7.9 and 15.5 (CH<sub>3</sub>), 24.1, 34.9 and 36.4 (CH<sub>2</sub>), 99.2, 107.3, 110.2, 114.9, 115.6, 116.6, 122.4, 126.3, 142.0, 142.9, 148.3, 150.2, 151.2 and 155.9 (Ar-C), 162.0 and 171.8 (C=O).

4.3.2.2.2. N-[5-(Diethylamino)pent-2-yl]-3-{3,5-dimethylfuro[3,2-g]coumarin-6-yl}propanamide **3c**, a yellow solid (1.02 g, 76%), m.p. 59-60 °C [HRMS: m/z calculated for C<sub>25</sub>H<sub>35</sub>N<sub>2</sub>O<sub>4</sub> (MH<sup>+</sup>) 427.2597. Found 427.2611];  $\delta_{\rm H}$  (400 MHz; CDCl<sub>3</sub>) 0.93 (6H, t, J = 6.5 Hz, 2 × CH<sub>2</sub>CH<sub>3</sub>), 1.04 (3H, d, J = 5.9 Hz, CHCH<sub>3</sub>), 1.37 (4H, m, CHCH<sub>2</sub>CH<sub>2</sub>), 2.25 [5H, m

(overlapping s and t), 3-CH<sub>3</sub> and CH<sub>2</sub>Ar], 2.39-2.48 (6H, series of signals,  $3 \times NCH_2$ ), 2.54 (3H, s, 5-CH<sub>3</sub>), 2.99 (2H, t, J = 6.5 Hz, CH<sub>2</sub>CO), 3.90 (1H, br s, NCH), 6.22 (1H, d, J = 6.7 Hz, NH), 7.29 (1H, s, ArH), 7.41 (1H, s, ArH) and 7.65 (1H, s, ArH);  $\delta_C$  (100 MHz; CDCl<sub>3</sub>) 7.8, 11.2, 15.4 and 20.6 (CH<sub>3</sub>), 23.3, 24.3, 34.6, 35.3, 46.6 and 52.6 (CH<sub>2</sub>), 45.0 (NCH), 99.2, 114.8, 115.6, 116.6, 122.7, 126.3, 142.9, 148.1, 150.1 and 155.9 (Ar-C), 162.0 and 171.3 (C=O).

4.3.2.2.3. 3-{3,5-Dimethylfuro[3,2-g]coumarin-6-yl]-N-[(pyridin-3-yl)methyl]propanamide **3d**, an off-white solid (1.07 g, 81%), m.p. 234-236 °C [HRMS: *m/z* calculated for  $C_{22}H_{21}N_2O_4$  (MH<sup>+</sup>) 377.1501. Found 377.1513];  $\delta_H$  (400 MHz; DMSO-*d*<sub>6</sub>) 2.25 (3H, s, 3-CH<sub>3</sub>), 2.37 (2H, t, *J* = 7.5 Hz, CH<sub>2</sub>Ar), 2.43 (3H, s, 5-CH<sub>3</sub>), 2.83 (2H, t, *J* = 7.5 Hz, CH<sub>2</sub>CO), 4.25 (2H, d, *J* = 5.7 Hz, NCH<sub>2</sub>), 7.17 (1H, m, ArH), 7.50-7.51 (2H, overlapping s and m, ArH), 7.80 (1H, s, ArH), 7.86 (1H, s, ArH), 8.37 (1H, d, *J* = 3.9, ArH) and 8.43 (2H, overlapping s and m, ArH and NH);  $\delta_C$  (100 MHz; DMSO-*d*<sub>6</sub>) 7.5 and 15.1 (CH<sub>3</sub>), 23.7, 33.9 and 39.9 (CH<sub>2</sub>), 98.7, 115.5, 115.9, 116.2, 122.3, 123.3, 125.8, 134.9, 135.0, 143.5, 147.8, 147.9, 148.7, 149.7 and 155.2 (Ar-C), 160.6 and 171.4 (C=O).

4.3.2.2.4 N-Benzyl-3-{3,5-dimethylfuro[3,2-g]coumarin-6-yl}propanamide **3e**, an off-white solid (1.07 g, 82%), m.p. 230-232 °C [HRMS: m/z calculated for C<sub>23</sub>H<sub>22</sub>NO<sub>4</sub> (MH<sup>+</sup>) 376.1549. Found 376.1565];  $\delta_{\rm H}$  (400 MHz; DMSO- $d_6$ ) 2.26 (3H, s, 3-CH<sub>3</sub>), 2.37 (2H, t, J = 7.5 Hz, CH<sub>2</sub>Ar), 2.45 (3H, s, 5-CH<sub>3</sub>), 2.84 (2H, t, J = 7.5 Hz, CH<sub>2</sub>CO), 4.21 (2H, s, NCH<sub>2</sub>), 7.15 (5H, s, ArH), 7.58 (1H, s, ArH), 7.85 (1H, s, ArH), 7.92 (1H, s, ArH) and 8.42 (1H, br s, NH);  $\delta_{\rm C}$  (100 MHz; DMSO- $d_6$ ) 7.6 and 15.2 (CH<sub>3</sub>), 23.8, 34.0 and 42.1 (CH<sub>2</sub>), 98.8, 115.7, 116.1, 116.4, 122.5, 125.9, 126.7, 127.2, 128.2, 139.5, 143.7, 148.0, 149.8 and 155.2 (Ar-C), 160.7 and 171.3 (C=O).

4.3.2.2.5. N-tert-*Butyl-3-{3,5-dimethylfuro[3,2-g]coumarin-6-yl]propanamide* **3f**, a white solid (0.75 g, 63%), m.p. 84-85 °C [HRMS: *m/z* calculated for  $C_{20}H_{24}NO_4$  (MH<sup>+</sup>) 342.1705. Found 342.1698];  $\delta_H$  (400 MHz; CDCl<sub>3</sub>) 1.28 [9H, s, C(CH<sub>3</sub>)<sub>3</sub>], 2.26 (3H, s, 3-CH<sub>3</sub>), 2.39 (2H, t, *J* = 7.5 Hz, CH<sub>2</sub>Ar), 2.54 (3H, s, 5-CH<sub>3</sub>), 2.97 (2H, t, *J* = 7.5 Hz, CH<sub>2</sub>CO), 5.67 (1H, br s, NH), 7.28 (1H, s, ArH), 7.41 (1H, s, ArH) and 7.65 (1H, s, ArH);  $\delta_C$  (100 MHz; CDCl<sub>3</sub>) 7.8, 15.5 and 28.6 (CH<sub>3</sub>), 24.2 and 36.0 (CH<sub>2</sub>), 51.0 [*C*(CH<sub>3</sub>)<sub>3</sub>], 99.1, 114.8, 115.6, 116.6, 122.8, 126.3, 142.8, 148.0, 150.1 and 155.8 (Ar-C), 162.0 and 171.3 (C=O).

4.3.2.2.6. 3-{3,5-Dimethylfuro[3,2-g]coumarin-6-yl}-N-propylpropanamide **3g**, a yellow solid (0.95 g, 83%), m.p. 211-213 °C [HRMS: m/z calculated for C<sub>19</sub>H<sub>22</sub>NO<sub>4</sub> (MH<sup>+</sup>) 328.1549. Found 328.1561];  $\delta_{\rm H}$  (400 MHz; DMSO- $d_6$ ) 0.75 (3H, t, J = 7.2 Hz, CH<sub>3</sub>), 1.33 (2H, m, CH<sub>2</sub>CH<sub>3</sub>), 2.24-2.29 (5H, overlapping s and t, 3-CH<sub>3</sub> and CH<sub>2</sub>Ar), 2.47 (3H, s, 5-CH<sub>3</sub>), 2.79 (2H, t, J = 7.2 Hz, CH<sub>2</sub>CO), 2.95 (2H, m, NCH<sub>2</sub>), 7.55 (1H, s, ArH), 7.82 (1H, s, ArH) 7.88 (1H, m, NH) and 7.92 (1H, s, ArH);  $\delta_{\rm C}$  (100 MHz; DMSO- $d_6$ ) 7.6, 11.4 and 15.3 (CH<sub>3</sub>), 23.9, 34.1, 39.5 and 40.4 (CH<sub>2</sub>), 51.0 (CH<sub>2</sub>CH<sub>3</sub>), 98.8, 115.7, 116.0, 122.6, 125.9, 143.7, 147.9, 149.8 and 155.2 (Ar-C), 160.8 and 171.2 (C=O).

#### 4.4. Biological evaluation.

The HIV-1 IN strand transfer inhibition assay was adapted from previously described methods.<sup>17</sup> Briefly, 0.15  $\mu$ M double-stranded biotinylated donor DNA (5'-biotin-GTGTGGAAAATCTCTAGCA-3' and 5'-ACTGCTAGAGATTTTCCACAC-3') was added to the wells of streptavidin-coated 96-well microtiter plates (R&D Systems, USA). Following incubation at room temperature for 60 minutes and a stringent wash step, 1  $\mu$ M purified

recombinant HIV-1 subtype B IN (in the presence of MgCl<sub>2</sub> and MnCl<sub>2</sub>) was assembled onto the pre-processed donor DNA through incubation for 30 minutes at 22 °C. Following a wash step, compounds 3a-g and Raltegravir were titrated into individual wells at a final concentration of 10  $\mu$ M. The microtiter plates were incubated for 30 minutes at 37 °C, washed and the strand transfer reaction was initiated through the addition of 0.25 µM double-stranded FITC-(5'-TGACCAAGGGCTAATTCACT-FITC-3' 5'labelled target DNA and AGTGAATTAGCCCTTGGTCA-FITC-3') in Hepes buffer containing MgCl<sub>2</sub> and MnCl<sub>2</sub>. After an incubation period of 60 minutes at 37 °C, the plates were washed as before and an alkaline phosphatase (AP) – conjugated anti-FITC secondary antibody (Sigma, USA) was added. Finally, the plates were washed and substrate (BluePhos, KPL, USA) was added to allow for detection at 620 nm using a microplate reader (xMark<sup>TM</sup>, Bio-Rad, USA). All inhibition values are the average of triplicate experiments.

#### 6. Acknowledgments

We thank MINTEK and Rhodes University for generous financial support and permission to publish these findings. T.O.O. gratefully acknowledges Obafemi Awolowo University, Ile-Ife, Nigeria for study leave.

#### 7. References and Notes

- 1. E. De Clercq. Rev. Med. Virol. 1996, 6, 97-117.
- N.A. Roberts, J.A. Martin, D. Kinchington, A.V. Broadhurst, J.C. Craig, I.B. Duncan, S.A. Galpin, B.K. Handa, J. Kay, A. Krohn, R.W. Lambert, J.H. Merreit, J.S. Mills, K.E.B. Parkes, S. Redshaw, A.J. Ritchie, D.L. Taylor, G.J. Thomas and P.J. Machin. *Science* 1990, 248, 358-361.
- R.T., Davey, Jr., R.L. Dewar, G.F. Reed, M.B. Vasudevachari, M.A. Polis, J.A. Kovacs, J. Falloon, R.E. Walker, H. Masur, S.E. Haneiwich, D.G. O'Neill, M.R. Decker, J.A. Metcalf, M.A. Deloria, O.L. Laskin, N. Salzmant, H.C. Lane. *Proc. Natl. Acad. Sci. USA*, **1993**, *90*, 5608-5612.
- 4. E. De Clercq. Pure & Appl. Chem. 1998, 70(3), 567-577.
- 5. D. da Silva, L. Van Wesenbeeck, D. Breilh, S. Reigadas, G. Anies, K. Van Baelen, P. Morlat, D. Neau, M. Dupon, L. Wittkop, H. Fleury and B. Masquelier. *J. Antimicrob. Chemother.* **2010**, *65*, 1262-1269.
- 6. M. Markowitz, B-Y. Nguyen, E. Gotuzzo, F. Mendo, W. Ratanasuwan, C. Kovacs, G. Prada, J.O. Morales-Ramirez, C.S. Crumpacker, R.D. Isaacs, H. Teppler, H. Wan, L.A. Wenning, L.R. Gilde. *JAIDS, Journal of Acquired Immune Deficiency Syndromes*, **2007**, *46*(2), 125-133.
- D.J. Hazuda, P. Felock, M. Witmer, A. Wolfe, K. Stillmock, J.A. Grobler, A. Espeseth, L. Gabryelski, W. Schleif, C. Blau and M.D. Miller. *Science* 2000, 287, 646-650.

- J.A. Grobler, K. Stillmock, B. Hu, M. Witmer, P. Felock, A.S. Espeseth, A. Wolfe, M. Egbertson, M. Bourgeois, J. Melamed, J. S. Wai, S. Young, J. Vacca and D.J. Hazuda. *Proc. Natl. Acad. Sci. USA*, 2002, 99(10), 6661–6666
- 9. A. Lacy and R. O'Kennedy. Curr. Pharm. Des., 2004, 10, 3797-3811.
- 10. M.A Stahmann, C.F. Huebner, K.P. Link. J. Biol. Chem., 138, (2), 513-27.
- 11. P.T. Kaye, M.A. Musa, A.T. Nchinda and X.W. Nocanda, *Synth. Commun.*, **2004**, *34*(14), 2575-2589.
- 12. T.O. Olomola, R. Klein, K.A. Lobb, Y. Sayed and P.T. Kaye. *Tetrahedron Lett.*, **2010**, *51*, 6325-6328.
- T.O. Olomola, R. Klein, N. Mautsa, Y. Sayed and P.T. Kaye. *Bioorg. & Med. Chem.*, 2013, 21, 1964-1971.
- 14. N.M. Shah and R.C. Shah. Ber. Dtsch. Chem. Ges. [Abteilung] B: Abhandlungen 1938, 71B, 2075-2081.
- 15. M.M. Garazd, Y.L. Garazd, A.S. Ogorodniichuk and V.P. Khilya. *Russian J. of Bioorg. Chem.* **2004**, *30* (3), 291-300.
- 16. J.K. MacLeod, B.R. Worth and R.J. Wells. Aust. J. Chem. 1978, 31, 1533-1544.
- 17. D.J. Hazuda, J.C. Hastings, A.L. Wolfe, and E.A. Emini. *Nucleic Acids Res.* **1994**, 22, 1121-1122.

## Novel Furocoumarins as Potential HIV-1 Integrase Inhibitors

Temitope O. Olomola,<sup>a</sup> Salerwe Mosebi,<sup>b</sup> Rosalyn Klein,<sup>a</sup> Telisha Traut-Johnstone,<sup>b</sup> Judy Coates,<sup>b</sup> Raymond Hewer <sup>b</sup> and Perry T. Kaye<sup>a</sup>\*

## **Graphical abstract**



## Novel Furocoumarins as Potential HIV-1 Integrase Inhibitors

Temitope O. Olomola,<sup>a</sup> Salerwe Mosebi,<sup>b</sup> Rosalyn Klein,<sup>a</sup> Telisha Traut-Johnstone,<sup>b</sup> Judy Coates,<sup>b</sup> Raymond Hewer <sup>b</sup> and Perry T. Kaye <sup>a</sup>\*

### Highlights.

- An HIV-1 IN active site model was constructed using sub-domain X-ray and NMR structures.
- The model was used to identify a furocoumarin system as a potential HIV-1 IN inhibitor.
- The potential HIV-1 IN inhibitor and six structural analogues have been synthesised.
- Some of the furocoumarin ligands exhibit low but statistically significant inhibition at  $10 \ \mu M$ .